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ABSTRACT
Objective: Stroke is defined as a sudden loss of brain function due to blockade/rupture of the brain’s blood vessels. Data collected by the Indonesian 
Stroke Foundation show that Indonesia ranks first in Asia as the country with the highest number of stroke sufferers. The purpose of this study was 
to determine the effectiveness of the use of gabapentin to reduce pain intensity and improve the quality of life of post-stroke neuropathic pain in NTB 
Province hospital patients.
Methods: This study was carried out in the period of June–July 2018. The population was all post-stroke neuropathic patients who received gabapentin 
therapy in regional general hospital, West Nusa Tenggara Province.
Results: The results of the study using questionnaire EQ-5D-3L after using gabapentin for 2 weeks. Patients experienced an improvement in the quality 
of life in each dimension items, namely the ability to walk/move from 6.7%, no problem to 60%, no self-care, 26.7% no problem to be 80% without 
problems, usual activities carried out from 13.3% had no problems to 46.7% had no problems, feeling of pain/discomfort from 60% having moderate 
problems to 60% had no problems, and anxiety/depression of 60% had no problem being 100% has no problem. While the measurement of the quality 
of life using the EQ-VAS questionnaire, there was a significant improvement in the quality of life between before and after using gabapentin at 32.66.
Conclusion: The use of gabapentin has effectiveness on reduction of pain intensity and the quality of life of post-stroke neuropathic patients in 
regional general hospital, West Nusa Tenggara Province year 2018.
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INTRODUCTION
Stroke is defined as a sudden loss of brain function caused by the 
blockage or the rupture of blood vessels of the brain [1,2]. Pathological 
classification stroke is ischemic stroke and hemorrhagic stroke [3]. 
Based on the data from the American Heart Association, stroke is the 
world’s second-leading cause of death in the age group of over 60 years 
and the fifth-leading cause of death in the age group of 15–59 years [4]. 
In the United States, it is recorded that almost every 45 s someone has 
a case of stroke, and every 4 s experienced a death due to stroke [5]. 
Medical treatment for post-stroke pain in Indonesia had already 
begun using tricyclic antidepressant groups such as amitriptyline 
and anticonvulsants groups such as gabapentin [6]. The response of 
patients using these two drugs is good but since 2013, both of them 
are no longer included in the list and price ceiling for the treatment of 
injury pain because of weak scientific evidence on the use of post-stroke 
pain so that the management of pain therapy post-stroke becomes less 
effective [7].
Several studies conducted a study comparing the therapeutic effects 
of gabapentin and amitriptyline in post-stroke with neuropathic pain. 
Both gabapentin and amitriptyline provided effective pain control in 
peripheral neuropathic pain. In addition, gabapentin was more effective, 
especially in paroxysmal shooting pain than other pain qualities [8]. 
The comparison between gabapentin and amitriptyline stated that 
there is no difference in the therapeutic effect of herniated nucleus 
pulposus [9]. This study aims to know the effectiveness of the usage of 
gabapentin to decrease pain intensity and improve the patients’ quality 
of life with neuropathic post-stroke in Poly Neurosurgery of Regional 
General Hospital, NTB.
METHODS
This study uses quasi-experimental, before the patient is given informed 
consent to retrieve patient data prospectively using the Wong-Baker 
Faces Pain Rating Scale (WBFPRC) to measure the reduction in pain 
intensity [10], and a questionnaire Euroqol 5 Dimension (EQ-5D) is used 
to measure the quality of life [11], analysis of variance and t-test were 
performed to analyze the mean difference in visual analog scale (VAS) and 
EQ-5D scores between subgroups of patients [12] and assess the health 
condition of the patient, comprising from EQ-5D-3L to measure improve 
the patient’s quality of life [13,14]. The research was conducted in Poly 
Neurosurgery of Regional General Hospital, NTB, in June–July 2018.
The samples in this study were all the stroke outpatients who undergo 
neuropathic pain in Provincial General Hospital, NTB, including 
inclusion and exclusion criteria. The effectiveness of therapy using 
Wong-Backer Faces Pain Rating Scale used to measure the reduction 
in pain intensity, EQ-5D-3L questionnaire, and EQ-VAS which is used to 
measure the patient’s quality of life.
EQ-5D-3L questionnaire consists of five dimensions: Mobility, self-care, 
activities, pain/discomfort, and anxiety/depression and in every 
dimension have a level such as no problem, moderate problems, and 
extreme problems. Levels of perceived problems are marked with (√) 
in each dimension and coded 1 in column 1, column 2 is coded 2, and 
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column 3 coded 3. Description: Column 1 = No problem in mobility, 
self-care, activities, pain/discomfort, and anxiety/depression. 
Column 2 = Moderate problems in mobility, self-care, activities, pain/
discomfort, and anxiety/depression. Column 3 = Extreme problems in 
mobility, self-care, activities, pain/discomfort, and anxiety/depression. 
EQ-VAS questionnaire (visual analog scale) is used to assess the health 
condition of the patient. A score of 100 is given for the best health 
conditions imaginable and a score of 0 for the worst health conditions 
that can be imagined. Questionnaires were given to patients before 
therapy and after 4 weeks of therapy.
RESULTS
In total, we recruited 15 study patients with post-stroke neuropathic. 
Demographic characteristics are summarized in Table 1. Patients age 
ranged from 20 to 83 years. Male accounted for 8 (53%) and education 
level up to senior high school 12 (80%).
Analysis of differences in pain intensity before and after gabapentin 
therapy to decrease pain intensity by the help of SPSS 16.0 for Windows, 
where the analysis uses paired sample t-test. Results of research 
conducted using the WBFPRC can be seen in Table 2.
Quality of life can be seen from the questionnaire respondents 
EQ-5D-3L. Questionnaire EQ-5D-3L has five dimensions: Mobility, 
self-care, activities, pain/discomfort, and anxiety/depression and has 
three levels of problems faced by patients: No problems, moderate 
problems, and extreme problems. Results of research conducted using 
the EQ-5D-3L questionnaire can be seen in Table 3.
EQ-VAS questionnaire is used to assess the imaginable health condition. 
In this questionnaire, the best health condition imaginable is rated 100 
and the worst health conditions are rated 0. The results of the research 
conducted using the EQ-VAS questionnaire can be seen in Table 4.
DISCUSSION
Based on Table 2, it showed a mean ± standard deviation result for 
the before data which is 8.06±1.38, after data 3.80±1.20, and both the 
data have difference in results which is 4.26±0.18 means that there is a 
decrease in pain as much as 4.26 in the treatment of gabapentin 2 × 300 
medication for 2 weeks also strengthened by the results of a p<0.05 so 
that there are significant differences in before and after treatment. This 
research may indicate that the use of gabapentin 300 mg 2 times daily 
for 2 weeks has effectiveness in reducing pain intensity, results from 
this study also strengthened with a previous study conducted where 
gabapentin is effective in reducing the intensity of the neuropathic 
post-stroke pain [6].
This is consistent with the theory that gabapentin may take effect 
after 1–2 weeks of usage and help reduce pain when used for at least 
2–3 months [6]. Gabapentin also has the effect of which can reduce 
pain in patients with painful diabetic neuropathy, it is supported by 
the previous studies that have been done using gabapentin to patients 
with painful diabetic neuropathy [15]. The previous studies conducted 
compared gabapentin with amitriptyline, where it was obtained that 
gabapentin amitriptyline is superior in terms of reducing pain [16].
Based on the results of the EQ-5D-3L questionnaire in Table 3 on the 
quality of life with five dimensions and three levels of problems that are 
checked by the patient showed patients with post-stroke neuropathic 
pain who used gabapentin experienced a perceived problem before 
using gabapentin, whether it be no problem, moderate problems, and 
extreme problems. The highest perceived problem is mobility which 
holds 73,3% from 11 of 15 total patients, three patients experience 
extreme problems, and one patient experiences no problem. Self-care is 
as much as 66.7% in experiencing moderate problems and no problem 
is experienced at a percentage of 26.7%, and one patient experiences 
extreme problems. Patients also experienced problems in daily 
activities, 60% in moderate problems, 26.7% in extreme problems, and 
13.3% in no problem. Pain/discomfort is experienced at a percentage 
of 60% in moderate problems and 40% in extreme problems. The least 
perceived problem is anxiety or depression where 40% of patients 
experience moderate problems and no problem is at 60%. Even though 
the patient felt pain, most patients do not experience feelings of 
depression or anxiety with pain being felt.
After the usage of gabapentin for 2 weeks, the percentage of patients who 
experience pain/discomfort decreased from 60% in experiencing extreme 
problems to 40% in experiencing moderate problems. The percentage 
of mobility decreased from 73.3% to 40% in experiencing moderate 
problems and an increase in experiencing little to no problem from 6.7% 
to 60%. Percentage of experiencing moderate problems in daily activities 
fell from 60% to 53.3%. Self-care percentage of experiencing little to no 
problems increased from 66.7% to 80%. This proves the effectiveness of 
gabapentin as a treatment of post-stroke neuropathic pain [17].
CONCLUSION
From the results of research conducted in NTB Regional General 
Hospital, it can be concluded that the measurement of pain intensity 
using the WBFPRC to measure the pain patients feel experienced a 
significant reduction in pain intensity between before and after the 
use of gabapentin as big as 4.26±0.18. Measurement of quality of life 
using the EQ-5D-3L questionnaire to increase the quality of life in all 
its dimensions, namely mobility from 6.7% to 60% in experiencing no 
problem, self-care from 26.7% to 80% in experiencing no problem, 
daily activities from 13.3% to 46.7% in experiencing no problem, 
pain/discomfort from 60% of experiencing moderate problems to 
60% of experiencing no problems, and anxiety/depression of 60% 
in experiencing no problem to 100% of experiencing no problem. 
Measurement of the quality of life using the EQ-VAS questionnaire to 
assess health conditions that can be imagined by the patient showed a 
significant increase in quality of life between before and after the usage 
of gabapentin in the amount of 32.66.
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Table 2: Pain intensity difference before and after the use of 
gabapentin
Group Mean±SD Δ p
Before 8.06±1.38 4.26±0.18 0.029*
After 3.80±1.20
SD: Standard deviation. *p<0.05, Δ: Increase adherence, p value of paired 
sample t-test, SD: Standard deviation
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Table 3: Patient response to every dimension of the EQ‑5D‑3L questionnaire
Dimension Before treatment After treatment
NP, n (%) MP, n (%) EP, n (%) NP, n (%) MP, n (%) EP, n (%)
Mobility 1 (6.7) 11 (73.3) 3 (20) 9 (60) 6 (40) 0 (0)
Self-care 4 (26.7) 10 (66.7) 1 (6.7) 12 (80) 3 (20) 0 (0)
Daily activities 2 (13.3) 9 (60) 4 (26.7) 7 (46.7) 8 (53.3) 0 (0)
Pain/discomfort 0 (0) 9 (60) 6 (40) 9 (60) 6 (40) 0 (0)
Anxiety/depression 9 (60) 6 (40) 0 (0) 15 (100) 0 (0) 0 (0)
n: Number of patients, NB: No problem, MP: Moderate problems, EP: Extreme problems





*p<0.05, Δ: Increase adherence, the p value of a paired sample t-test, 
SD: Standard deviation
